The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 03, 2018

Filed:

Oct. 12, 2016
Applicant:

Ibc Pharmaceuticals, Inc., Morris Plains, NJ (US);

Inventors:

Chien-Hsing Chang, Downingtown, PA (US);

David M. Goldenberg, Mendham, NJ (US);

Edmund A. Rossi, Woodland Park, NJ (US);

Assignee:

IBC Pharmaceuticals, Inc., Morris Plains, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/48 (2006.01); C07K 16/28 (2006.01); C07K 14/56 (2006.01); C07K 14/54 (2006.01); C07K 14/52 (2006.01); C07K 16/00 (2006.01); C07K 14/535 (2006.01); C07K 14/505 (2006.01); C12N 9/12 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48423 (2013.01); A61K 47/481 (2013.01); A61K 47/48338 (2013.01); C07K 14/505 (2013.01); C07K 14/535 (2013.01); C07K 14/56 (2013.01); C07K 16/00 (2013.01); C07K 16/2887 (2013.01); C12N 9/12 (2013.01); C12Y 207/11011 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/64 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01);
Abstract

The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-α2b.


Find Patent Forward Citations

Loading…